[Correspondence] Optimal molecular selection to benefit from nivolumab–ipilimumab in clear-cell renal cell carcinoma

In his Comment in The Lancet Oncology, Tsunenori Kondo1 offered a pragmatic interpretation of the results of our BIONIKK randomised phase 2 trial2 in patients with frontline metastatic clear-cell renal cell carcinoma. However, we wish to respond to some of the arguments of its interpretation.